1	HIV/AIDS	_	_	NNP	_	_	_	_	_
2	continues	_	_	VBZ	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	one	_	_	CD	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	most	_	_	RBS	_	_	_	_	_
9	challenging	_	_	JJ	_	_	_	_	_
10	individual	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	public	_	_	JJ	_	_	_	_	_
13	health	_	_	NN	_	_	_	_	_
14	concerns	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	our	_	_	PRP$	_	_	_	_	_
17	days	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	According	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	latest	_	_	JJS	_	_	_	_	_
5	UNAIDS	_	_	NNP	_	_	_	_	_
6	data	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	2018	_	_	CD	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	roughly	_	_	RB	_	_	_	_	_
12	37.9	_	_	CD	_	_	_	_	_
13	million	_	_	CD	_	_	_	_	_
14	individuals	_	_	NNS	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	infected	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	HIV	_	_	NNP	_	_	_	_	_
19	globally	_	_	RB	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	while	_	_	IN	_	_	_	_	_
22	around	_	_	RB	_	_	_	_	_
23	770,000	_	_	CD	_	_	_	_	_
24	people	_	_	NNS	_	_	_	_	_
25	died	_	_	VBD	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	AIDS-related	_	_	JJ	_	_	_	_	_
28	illness	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	that	_	_	DT	_	_	_	_	_
3	same	_	_	JJ	_	_	_	_	_
4	year	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	estimated	_	_	VBN	_	_	_	_	_
8	1.7	_	_	CD	_	_	_	_	_
9	million	_	_	CD	_	_	_	_	_
10	new	_	_	JJ	_	_	_	_	_
11	infections	_	_	NNS	_	_	_	_	_
12	occurred	_	_	VBD	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	mainly	_	_	RB	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	unprotected	_	_	JJ	_	_	_	_	_
18	sexual	_	_	JJ	_	_	_	_	_
19	intercourse	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Investment	_	_	NN	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	field	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	considerable	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	cure	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	infection	_	_	NN	_	_	_	_	_
15	remains	_	_	VBZ	_	_	_	_	_
16	elusive	_	_	JJ	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Nonetheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	tremendous	_	_	JJ	_	_	_	_	_
4	advances	_	_	NNS	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	made	_	_	VBN	_	_	_	_	_
8	over	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	last	_	_	JJ	_	_	_	_	_
11	36	_	_	CD	_	_	_	_	_
12	years	_	_	NNS	_	_	_	_	_
13	since	_	_	IN	_	_	_	_	_
14	HIV-1	_	_	NNP	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	identified	_	_	VBN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	namely	_	_	RB	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	prevention	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	diagnostics	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	treatment	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	development	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	antiretroviral	_	_	JJ	_	_	_	_	_
5	drugs	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	introduction	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	highly	_	_	RB	_	_	_	_	_
11	active	_	_	JJ	_	_	_	_	_
12	antiretroviral	_	_	JJ	_	_	_	_	_
13	therapy	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	HAART	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	mid-1990s	_	_	NNS	_	_	_	_	_
20	—	_	_	:	_	_	_	_	_
21	currently	_	_	RB	_	_	_	_	_
22	referred	_	_	VBN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	combination	_	_	NN	_	_	_	_	_
26	antiretroviral	_	_	JJ	_	_	_	_	_
27	therapy	_	_	NN	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	cART	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	—	_	_	:	_	_	_	_	_
32	led	_	_	VBD	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	a	_	_	DT	_	_	_	_	_
35	dramatic	_	_	JJ	_	_	_	_	_
36	shift	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	AIDS	_	_	NN	_	_	_	_	_
39	from	_	_	IN	_	_	_	_	_
40	a	_	_	DT	_	_	_	_	_
41	fatal	_	_	JJ	_	_	_	_	_
42	disease	_	_	NN	_	_	_	_	_
43	into	_	_	IN	_	_	_	_	_
44	a	_	_	DT	_	_	_	_	_
45	chronic	_	_	JJ	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	often	_	_	RB	_	_	_	_	_
48	stable	_	_	JJ	_	_	_	_	_
49	medical	_	_	JJ	_	_	_	_	_
50	condition	_	_	NN	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	cART	_	_	NNP	_	_	_	_	_
5	contributed	_	_	VBD	_	_	_	_	_
6	decisively	_	_	RB	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	steady	_	_	JJ	_	_	_	_	_
10	decrease	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	number	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	HIV-related	_	_	JJ	_	_	_	_	_
16	deaths	_	_	NNS	_	_	_	_	_
17	since	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	first	_	_	JJ	_	_	_	_	_
20	years	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	new	_	_	JJ	_	_	_	_	_
24	millennium	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Antiretroviral	_	_	JJ	_	_	_	_	_
2	drugs	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	found	_	_	VBN	_	_	_	_	_
7	useful	_	_	JJ	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	prevention	_	_	NN	_	_	_	_	_
11	field	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	particularly	_	_	RB	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	post-exposure	_	_	JJ	_	_	_	_	_
16	prophylaxis	_	_	NN	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	mother-to-child	_	_	NN	_	_	_	_	_
19	transmission	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Treatment	_	_	NN	_	_	_	_	_
2	as	_	_	IN	_	_	_	_	_
3	prevention	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	pre-exposure	_	_	NN	_	_	_	_	_
6	prophylaxis	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	PrEP	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	further	_	_	RBR	_	_	_	_	_
12	contributed	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	reduction	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	sexually	_	_	RB	_	_	_	_	_
18	transmitted	_	_	VBN	_	_	_	_	_
19	HIV	_	_	NN	_	_	_	_	_
20	infections	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Long-lasting	_	_	JJ	_	_	_	_	_
2	injectable	_	_	JJ	_	_	_	_	_
3	products	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	antiretroviral-based	_	_	JJ	_	_	_	_	_
6	microbicides	_	_	NNS	_	_	_	_	_
7	that	_	_	WDT	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	currently	_	_	RB	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	late	_	_	JJ	_	_	_	_	_
12	stages	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	clinical	_	_	JJ	_	_	_	_	_
15	development	_	_	NN	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	regulatory	_	_	JJ	_	_	_	_	_
18	approval	_	_	NN	_	_	_	_	_
19	may	_	_	MD	_	_	_	_	_
20	soon	_	_	RB	_	_	_	_	_
21	provide	_	_	VB	_	_	_	_	_
22	new	_	_	JJ	_	_	_	_	_
23	options	_	_	NNS	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	prevention	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Gene	_	_	NNP	_	_	_	_	_
2	therapy	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	use	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	broadly	_	_	RB	_	_	_	_	_
8	neutralizing	_	_	VBG	_	_	_	_	_
9	antibodies	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	attracting	_	_	VBG	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	great	_	_	JJ	_	_	_	_	_
15	deal	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	interest	_	_	NN	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	possible	_	_	JJ	_	_	_	_	_
20	approaches	_	_	NNS	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	HIV/AIDS	_	_	NNP	_	_	_	_	_
23	management	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Still	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	different	_	_	JJ	_	_	_	_	_
4	challenges	_	_	NNS	_	_	_	_	_
5	remain	_	_	VBP	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	anti-HIV	_	_	NNP	_	_	_	_	_
8	drug	_	_	NN	_	_	_	_	_
9	therapy/prophylaxis	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	these	_	_	DT	_	_	_	_	_
13	include	_	_	VBP	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	following	_	_	VBG	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	among	_	_	IN	_	_	_	_	_
18	others	_	_	NNS	_	_	_	_	_
19	:	_	_	:	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	i	_	_	CD	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	onset	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	severe	_	_	JJ	_	_	_	_	_
27	adverse	_	_	JJ	_	_	_	_	_
28	effects	_	_	NNS	_	_	_	_	_
29	leading	_	_	VBG	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	discontinuation	_	_	NN	_	_	_	_	_
33	or	_	_	CC	_	_	_	_	_
34	interruption	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	therapy	_	_	NN	_	_	_	_	_
37	or	_	_	CC	_	_	_	_	_
38	even	_	_	RB	_	_	_	_	_
39	prophylaxis	_	_	NN	_	_	_	_	_
40	;	_	_	:	_	_	_	_	_
41	(	_	_	-LRB-	_	_	_	_	_
42	ii	_	_	NN	_	_	_	_	_
43	)	_	_	-RRB-	_	_	_	_	_
44	sub-optimal	_	_	JJ	_	_	_	_	_
45	biodistribution	_	_	NN	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	pharmacokinetics	_	_	NNS	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	particularly	_	_	RB	_	_	_	_	_
50	in	_	_	IN	_	_	_	_	_
51	reservoir	_	_	NN	_	_	_	_	_
52	sites	_	_	NNS	_	_	_	_	_
53	or	_	_	CC	_	_	_	_	_
54	mucosae	_	_	NNS	_	_	_	_	_
55	involved	_	_	VBN	_	_	_	_	_
56	in	_	_	IN	_	_	_	_	_
57	sexual	_	_	JJ	_	_	_	_	_
58	transmission	_	_	NN	_	_	_	_	_
59	;	_	_	:	_	_	_	_	_
60	(	_	_	-LRB-	_	_	_	_	_
61	iii	_	_	NN	_	_	_	_	_
62	)	_	_	-RRB-	_	_	_	_	_
63	the	_	_	DT	_	_	_	_	_
64	occurrence	_	_	NN	_	_	_	_	_
65	of	_	_	IN	_	_	_	_	_
66	viral	_	_	JJ	_	_	_	_	_
67	resistance	_	_	NN	_	_	_	_	_
68	;	_	_	:	_	_	_	_	_
69	(	_	_	-LRB-	_	_	_	_	_
70	iv	_	_	NN	_	_	_	_	_
71	)	_	_	-RRB-	_	_	_	_	_
72	troublesome	_	_	JJ	_	_	_	_	_
73	regimens	_	_	NNS	_	_	_	_	_
74	and/or	_	_	JJ	_	_	_	_	_
75	drug	_	_	NN	_	_	_	_	_
76	delivery	_	_	NN	_	_	_	_	_
77	routes	_	_	NNS	_	_	_	_	_
78	that	_	_	WDT	_	_	_	_	_
79	lead	_	_	VBP	_	_	_	_	_
80	to	_	_	TO	_	_	_	_	_
81	poor	_	_	JJ	_	_	_	_	_
82	adherence	_	_	NN	_	_	_	_	_
83	by	_	_	IN	_	_	_	_	_
84	patients/users	_	_	NNS	_	_	_	_	_
85	;	_	_	:	_	_	_	_	_
86	(	_	_	-LRB-	_	_	_	_	_
87	v	_	_	NN	_	_	_	_	_
88	)	_	_	-RRB-	_	_	_	_	_
89	low	_	_	JJ	_	_	_	_	_
90	stability	_	_	NN	_	_	_	_	_
91	and	_	_	CC	_	_	_	_	_
92	reduced	_	_	VBN	_	_	_	_	_
93	shelf-life	_	_	NN	_	_	_	_	_
94	of	_	_	IN	_	_	_	_	_
95	active	_	_	JJ	_	_	_	_	_
96	molecules	_	_	NNS	_	_	_	_	_
97	,	_	_	,	_	_	_	_	_
98	which	_	_	WDT	_	_	_	_	_
99	may	_	_	MD	_	_	_	_	_
100	be	_	_	VB	_	_	_	_	_
101	particularly	_	_	RB	_	_	_	_	_
102	challenging	_	_	JJ	_	_	_	_	_
103	in	_	_	IN	_	_	_	_	_
104	tropical	_	_	JJ	_	_	_	_	_
105	climates	_	_	NNS	_	_	_	_	_
106	and	_	_	CC	_	_	_	_	_
107	low-resource	_	_	JJ	_	_	_	_	_
108	regions	_	_	NNS	_	_	_	_	_
109	lacking	_	_	VBG	_	_	_	_	_
110	adequate	_	_	JJ	_	_	_	_	_
111	refrigerated	_	_	VBN	_	_	_	_	_
112	distribution	_	_	NN	_	_	_	_	_
113	channels	_	_	NNS	_	_	_	_	_
114	and	_	_	CC	_	_	_	_	_
115	storage	_	_	NN	_	_	_	_	_
116	;	_	_	:	_	_	_	_	_
117	(	_	_	-LRB-	_	_	_	_	_
118	vi	_	_	NN	_	_	_	_	_
119	)	_	_	-RRB-	_	_	_	_	_
120	lack	_	_	NN	_	_	_	_	_
121	of	_	_	IN	_	_	_	_	_
122	suitable	_	_	JJ	_	_	_	_	_
123	dosage	_	_	NN	_	_	_	_	_
124	forms	_	_	NNS	_	_	_	_	_
125	for	_	_	IN	_	_	_	_	_
126	particular	_	_	JJ	_	_	_	_	_
127	populations	_	_	NNS	_	_	_	_	_
128	(	_	_	-LRB-	_	_	_	_	_
129	e.	_	_	FW	_	_	_	_	_
130	g.	_	_	FW	_	_	_	_	_
131	,	_	_	,	_	_	_	_	_
132	children	_	_	NNS	_	_	_	_	_
133	and	_	_	CC	_	_	_	_	_
134	women	_	_	NNS	_	_	_	_	_
135	)	_	_	-RRB-	_	_	_	_	_
136	;	_	_	:	_	_	_	_	_
137	(	_	_	-LRB-	_	_	_	_	_
138	vii	_	_	CD	_	_	_	_	_
139	)	_	_	-RRB-	_	_	_	_	_
140	costly	_	_	JJ	_	_	_	_	_
141	drug	_	_	NN	_	_	_	_	_
142	products	_	_	NNS	_	_	_	_	_
143	that	_	_	WDT	_	_	_	_	_
144	are	_	_	VBP	_	_	_	_	_
145	often	_	_	RB	_	_	_	_	_
146	inaccessible	_	_	JJ	_	_	_	_	_
147	to	_	_	TO	_	_	_	_	_
148	populations	_	_	NNS	_	_	_	_	_
149	in	_	_	IN	_	_	_	_	_
150	need	_	_	NN	_	_	_	_	_
151	of	_	_	IN	_	_	_	_	_
152	therapy/prophylaxis	_	_	NN	_	_	_	_	_
153	;	_	_	:	_	_	_	_	_
154	and	_	_	CC	_	_	_	_	_
155	(	_	_	-LRB-	_	_	_	_	_
156	viii	_	_	NN	_	_	_	_	_
157	)	_	_	-RRB-	_	_	_	_	_
158	social	_	_	JJ	_	_	_	_	_
159	and	_	_	CC	_	_	_	_	_
160	legal	_	_	JJ	_	_	_	_	_
161	constraints	_	_	NNS	_	_	_	_	_
162	resulting	_	_	VBG	_	_	_	_	_
163	in	_	_	IN	_	_	_	_	_
164	poor	_	_	JJ	_	_	_	_	_
165	access	_	_	NN	_	_	_	_	_
166	to	_	_	TO	_	_	_	_	_
167	and	_	_	CC	_	_	_	_	_
168	the	_	_	DT	_	_	_	_	_
169	discontinuation	_	_	NN	_	_	_	_	_
170	of	_	_	IN	_	_	_	_	_
171	anti-HIV	_	_	JJ	_	_	_	_	_
172	therapy/prophylaxis	_	_	NN	_	_	_	_	_
173	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	response	_	_	NN	_	_	_	_	_
3	from	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	scientific	_	_	JJ	_	_	_	_	_
6	community	_	_	NN	_	_	_	_	_
7	could	_	_	MD	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	more	_	_	RBR	_	_	_	_	_
11	affirmative	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	novel	_	_	JJ	_	_	_	_	_
15	ideas	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	concepts	_	_	NNS	_	_	_	_	_
18	have	_	_	VBP	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	emerging	_	_	VBG	_	_	_	_	_
21	throughout	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	last	_	_	JJ	_	_	_	_	_
24	decade	_	_	NN	_	_	_	_	_
25	or	_	_	CC	_	_	_	_	_
26	so	_	_	RB	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	More	_	_	RBR	_	_	_	_	_
2	important	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	innovative	_	_	JJ	_	_	_	_	_
5	products	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	now	_	_	RB	_	_	_	_	_
8	under	_	_	IN	_	_	_	_	_
9	development	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	holding	_	_	VBG	_	_	_	_	_
12	great	_	_	JJ	_	_	_	_	_
13	promise	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	mitigating	_	_	VBG	_	_	_	_	_
16	many	_	_	JJ	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	challenges	_	_	NNS	_	_	_	_	_
20	identified	_	_	VBN	_	_	_	_	_
21	above	_	_	RB	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	Special	_	_	NNP	_	_	_	_	_
3	Issue	_	_	NNP	_	_	_	_	_
4	presents	_	_	VBZ	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	exciting	_	_	JJ	_	_	_	_	_
7	series	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	reviews	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	original	_	_	JJ	_	_	_	_	_
12	research	_	_	NN	_	_	_	_	_
13	articles	_	_	NNS	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	eminent	_	_	JJ	_	_	_	_	_
16	scientists	_	_	NNS	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	academia	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	different	_	_	JJ	_	_	_	_	_
21	nonprofit	_	_	JJ	_	_	_	_	_
22	organizations	_	_	NNS	_	_	_	_	_
23	involved	_	_	VBN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	development	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	antiretroviral	_	_	JJ	_	_	_	_	_
29	drug	_	_	NN	_	_	_	_	_
30	products	_	_	NNS	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	focusing	_	_	VBG	_	_	_	_	_
33	mainly	_	_	RB	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	novel	_	_	JJ	_	_	_	_	_
36	strategies	_	_	NNS	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	formulation	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	delivery	_	_	NN	_	_	_	_	_
42	of	_	_	IN	_	_	_	_	_
43	anti-HIV	_	_	JJ	_	_	_	_	_
44	compounds	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Innovative	_	_	JJ	_	_	_	_	_
2	approaches	_	_	NNS	_	_	_	_	_
3	towards	_	_	IN	_	_	_	_	_
4	improved	_	_	VBN	_	_	_	_	_
5	gene	_	_	NN	_	_	_	_	_
6	therapy	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	immunotherapy	_	_	NN	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	addressed	_	_	VBN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	presented	_	_	VBN	_	_	_	_	_
3	reports	_	_	NNS	_	_	_	_	_
4	provide	_	_	VBP	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	only	_	_	RB	_	_	_	_	_
7	interesting	_	_	JJ	_	_	_	_	_
8	overviews	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	opinion	_	_	NN	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	recent	_	_	JJ	_	_	_	_	_
13	developments	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	broad	_	_	JJ	_	_	_	_	_
17	field	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	antiretroviral	_	_	JJ	_	_	_	_	_
20	therapy/prophylaxis	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	drug	_	_	NN	_	_	_	_	_
23	delivery	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	but	_	_	CC	_	_	_	_	_
26	also	_	_	RB	_	_	_	_	_
27	describe	_	_	VB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	development	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	new	_	_	JJ	_	_	_	_	_
32	products	_	_	NNS	_	_	_	_	_
33	that	_	_	WDT	_	_	_	_	_
34	are	_	_	VBP	_	_	_	_	_
35	currently	_	_	RB	_	_	_	_	_
36	tracked	_	_	VBN	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	clinical	_	_	JJ	_	_	_	_	_
39	testing	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	Special	_	_	NNP	_	_	_	_	_
3	Issue	_	_	NNP	_	_	_	_	_
4	starts	_	_	VBZ	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	interesting	_	_	JJ	_	_	_	_	_
8	review	_	_	NN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	Tsukamoto	_	_	NNP	_	_	_	_	_
11	at	_	_	IN	_	_	_	_	_
12	Kindai	_	_	NNP	_	_	_	_	_
13	University	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	Japan	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	strategies	_	_	NNS	_	_	_	_	_
19	explored	_	_	VBN	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	curing	_	_	VBG	_	_	_	_	_
22	HIV	_	_	NN	_	_	_	_	_
23	infection	_	_	NN	_	_	_	_	_
24	using	_	_	VBG	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	combination	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	gene	_	_	NN	_	_	_	_	_
29	therapy	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	host	_	_	NN	_	_	_	_	_
32	immunization	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	particular	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	author	_	_	NN	_	_	_	_	_
6	emphasizes	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	possible	_	_	JJ	_	_	_	_	_
9	role	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	anti-HIV	_	_	JJ	_	_	_	_	_
12	intracellular	_	_	JJ	_	_	_	_	_
13	immunization	_	_	NN	_	_	_	_	_
14	using	_	_	VBG	_	_	_	_	_
15	gene	_	_	NN	_	_	_	_	_
16	silencing	_	_	VBG	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	among	_	_	IN	_	_	_	_	_
19	other	_	_	JJ	_	_	_	_	_
20	approaches	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	protection	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	bone	_	_	NN	_	_	_	_	_
27	marrow	_	_	NN	_	_	_	_	_
28	hematopoietic	_	_	JJ	_	_	_	_	_
29	stem/progenitor	_	_	NN	_	_	_	_	_
30	cells	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Still	_	_	RB	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	same	_	_	JJ	_	_	_	_	_
5	field	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	Düzgüneş	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	Konopka	_	_	NNP	_	_	_	_	_
10	at	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	University	_	_	NNP	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	Pacific	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	USA	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	contributed	_	_	VBD	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	stimulating	_	_	VBG	_	_	_	_	_
22	review	_	_	NN	_	_	_	_	_
23	on	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	potential	_	_	JJ	_	_	_	_	_
26	strategy	_	_	NN	_	_	_	_	_
27	for	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	eradication	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	cellular	_	_	JJ	_	_	_	_	_
32	reservoirs	_	_	NNS	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	HIV	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	thought-provoking	_	_	JJ	_	_	_	_	_
3	piece	_	_	NN	_	_	_	_	_
4	explores	_	_	VBZ	_	_	_	_	_
5	how	_	_	WRB	_	_	_	_	_
6	such	_	_	PDT	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	objective	_	_	NN	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	achieved	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	using	_	_	VBG	_	_	_	_	_
14	suicide	_	_	NN	_	_	_	_	_
15	gene	_	_	NN	_	_	_	_	_
16	therapy	_	_	NN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	killing	_	_	VBG	_	_	_	_	_
19	HIV-infected	_	_	JJ	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	excision	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	chromosome-integrated	_	_	JJ	_	_	_	_	_
25	viral	_	_	JJ	_	_	_	_	_
26	DNA	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	cytotoxic	_	_	JJ	_	_	_	_	_
30	liposomes	_	_	NNS	_	_	_	_	_
31	targeted	_	_	VBN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	latency-reversed	_	_	JJ	_	_	_	_	_
34	HIV-infected	_	_	JJ	_	_	_	_	_
35	cells	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_

